Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study.
IF 4.3 3区 材料科学Q1 ENGINEERING, ELECTRICAL & ELECTRONIC
{"title":"Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study.","authors":"Zhaopeng Huang, Jian Tang, Ruibin Wu, Shunhua Long, Wenke Chen, Tingna Lu, Qiuyue Xia, Yanhui Wu, Hongsheng Yang, Qingfan Yang, Zicheng Huang, Qin Guo, Miao Li, Xiang Gao, Kang Chao","doi":"10.1177/17562848241281218","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>No head-to-head trial directly compares the effectiveness of vedolizumab (VDZ) and infliximab (IFX) in patients with ulcerative colitis (UC) who were naïve to biologic therapy.</p><p><strong>Objectives: </strong>We aimed to compare the clinical and endoscopic effectiveness of VDZ and IFX in biologic-naïve patients with UC in real-world settings.</p><p><strong>Design: </strong>It was a multicenter, observational, real-world cohort study conducted at five centers.</p><p><strong>Methods: </strong>Patients diagnosed with UC and treated with either IFX or VDZ as their first-line biologic therapy were retrospectively enrolled. Steroid-free remission, clinical response, clinical remission, and endoscopic healing at week 14 and week 52 were compared between the two groups after propensity score weighting.</p><p><strong>Results: </strong>A total of 199 patients (117 VDZ and 82 IFX) were included in the study. There were no significant differences in steroid-free remission (64.6% vs 56.1%, <i>p</i> = 0.224), clinical response (83.4% vs 73.4%, <i>p</i> = 0.086), or clinical remission (69.4% vs 60.1%, <i>p</i> = 0.174) at week 14. However, VDZ showed better results in steroid-free remission (67.5% vs 44.4%, <i>p</i> = 0.004), clinical response (69.7% vs 47.1%, <i>p</i> = 0.005), and clinical remission (67.5% vs 44.4%, <i>p</i> = 0.004) at week 52. In terms of endoscopic healing, VDZ was similar to IFX at week 14 (25.7% vs 17.4%, <i>p</i> = 0.185), but VDZ had a significantly higher rate at week 52 (29.5% vs 11.8%, <i>p</i> = 0.027). VDZ was found to be superior to IFX in therapeutic continuation (hazard ratio = 0.339, 95% CI: 0.187-0.614, <i>p</i> < 0.001). The rate of adverse events was similar between the two groups (6.8% vs 8.5%, <i>p</i> = 0.655).</p><p><strong>Conclusion: </strong>VDZ demonstrated similar clinical and endoscopic effectiveness to IFX at week 14 in biologic-naïve patients with UC, but appeared to be superior at week 52. The safety outcomes were comparable between the groups.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483708/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848241281218","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Background: No head-to-head trial directly compares the effectiveness of vedolizumab (VDZ) and infliximab (IFX) in patients with ulcerative colitis (UC) who were naïve to biologic therapy.
Objectives: We aimed to compare the clinical and endoscopic effectiveness of VDZ and IFX in biologic-naïve patients with UC in real-world settings.
Design: It was a multicenter, observational, real-world cohort study conducted at five centers.
Methods: Patients diagnosed with UC and treated with either IFX or VDZ as their first-line biologic therapy were retrospectively enrolled. Steroid-free remission, clinical response, clinical remission, and endoscopic healing at week 14 and week 52 were compared between the two groups after propensity score weighting.
Results: A total of 199 patients (117 VDZ and 82 IFX) were included in the study. There were no significant differences in steroid-free remission (64.6% vs 56.1%, p = 0.224), clinical response (83.4% vs 73.4%, p = 0.086), or clinical remission (69.4% vs 60.1%, p = 0.174) at week 14. However, VDZ showed better results in steroid-free remission (67.5% vs 44.4%, p = 0.004), clinical response (69.7% vs 47.1%, p = 0.005), and clinical remission (67.5% vs 44.4%, p = 0.004) at week 52. In terms of endoscopic healing, VDZ was similar to IFX at week 14 (25.7% vs 17.4%, p = 0.185), but VDZ had a significantly higher rate at week 52 (29.5% vs 11.8%, p = 0.027). VDZ was found to be superior to IFX in therapeutic continuation (hazard ratio = 0.339, 95% CI: 0.187-0.614, p < 0.001). The rate of adverse events was similar between the two groups (6.8% vs 8.5%, p = 0.655).
Conclusion: VDZ demonstrated similar clinical and endoscopic effectiveness to IFX at week 14 in biologic-naïve patients with UC, but appeared to be superior at week 52. The safety outcomes were comparable between the groups.
背景：目前还没有头对头试验直接比较维多珠单抗（VDZ）和英夫利昔单抗（IFX）对接受过生物治疗的溃疡性结肠炎（UC）患者的疗效：我们旨在比较VDZ和IFX在现实世界中对生物制剂治疗无效的UC患者的临床和内镜疗效：这是一项多中心、观察性、真实世界队列研究，在五个中心进行：方法：回顾性纳入被诊断为UC并接受IFX或VDZ作为一线生物治疗的患者。经过倾向得分加权后，比较了两组患者在第14周和第52周的无类固醇缓解、临床反应、临床缓解和内镜愈合情况：研究共纳入199名患者（117名VDZ患者和82名IFX患者）。第14周时，无类固醇缓解率（64.6% vs 56.1%，P = 0.224）、临床反应率（83.4% vs 73.4%，P = 0.086）或临床缓解率（69.4% vs 60.1%，P = 0.174）均无明显差异。然而，在第52周时，VDZ在无类固醇缓解（67.5% vs 44.4%，p = 0.004）、临床反应（69.7% vs 47.1%，p = 0.005）和临床缓解（67.5% vs 44.4%，p = 0.004）方面显示出更好的效果。在内镜愈合方面，第14周时VDZ与IFX相似（25.7% vs 17.4%，p = 0.185），但第52周时VDZ的愈合率明显更高（29.5% vs 11.8%，p = 0.027）。VDZ在继续治疗方面优于IFX（危险比=0.339，95% CI：0.187-0.614，P=0.655）：结论：在第14周时，VDZ对生物制剂无效的UC患者的临床和内镜疗效与IFX相似，但在第52周时似乎更胜一筹。两组的安全性结果相当。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
